Patents by Inventor J. Michael McIntosh
J. Michael McIntosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040204362Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: ApplicationFiled: May 6, 2004Publication date: October 14, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Jacob Scott Nielsen, Robert M. Jones
-
Publication number: 20040192886Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 21, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Publication number: 20040192610Abstract: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa12 is des-Xaa12 or any amino acid.Type: ApplicationFiled: April 20, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Sigin Luo
-
Patent number: 6797808Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: January 28, 2000Date of Patent: September 28, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
-
Patent number: 6767896Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.Type: GrantFiled: May 26, 2000Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: J. Michael McIntosh, Baldomero M. Olivera, Lourdes J. Cruz, Gloria P. Corpuz, Robert M. Jones, James E. Garrett
-
Patent number: 6767895Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: GrantFiled: June 29, 2001Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Craig S. Walker, Reshma Shetty, Elsie C. Jimenez, J. Michael McIntosh, Baldomero M. Olivera, Maren Watkins, Robert M. Jones, Gregory S. Shen
-
Patent number: 6762165Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: December 28, 2000Date of Patent: July 13, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20040132663Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: January 29, 2004Publication date: July 8, 2004Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Patent number: 6727226Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: GrantFiled: July 23, 2001Date of Patent: April 27, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Lourdes J. Cruz, Robert M. Jones, G. Edward Cartier, John D. Wagstaff
-
Publication number: 20030224343Abstract: The invention relates to &kgr;-PVIIA-related conotoxins and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a neurological organ. These conotoxins can also be used for arresting, protecting or preserving somatic cells.Type: ApplicationFiled: January 28, 2003Publication date: December 4, 2003Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Karen Pemberton-Goodman, Robert M. Jones, Davis L. Temple, J. Michael McIntosh, Baldomero M. Olivera
-
Publication number: 20030181368Abstract: The present invention is directed to kappaA (&kgr;A) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The &kgr;A conopeptides include unglycosylated and O-glycosylated peptides.Type: ApplicationFiled: May 7, 2002Publication date: September 25, 2003Inventors: Richard T. Layer, Karen E. Pemberton, Robert M. Jones, James L. Garrett, Baldomero M. Olivera, J. Michael McIntosh, David R. Hillyard, Michelle Grilley, Maren Watkins, Ameurfina D. Santos, Glenn Zafaralla, A. Grey Craig
-
Publication number: 20030166560Abstract: The present invention is directed to P-superfamily conopeptides, to DNA encoding precursors of the P-superfamily conopeptides and to the precursor peptides.Type: ApplicationFiled: January 30, 2003Publication date: September 4, 2003Inventors: David Hooper, James E. Garrett, Gloria P. Corpuz, Lourdes J. Cruz, Baldomero M. Olivera, J. Michael McIntosh, Robert M. Jones
-
Publication number: 20030144210Abstract: The invention relates to &ggr;-carboxyglutamate containing conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 31, 2002Publication date: July 31, 2003Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Craig S. Walker, Maren Watkins, Robert M. Jones
-
Publication number: 20030119731Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: June 26, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Publication number: 20030109670Abstract: The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: February 11, 2002Publication date: June 12, 2003Applicant: University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Lourdes J. Cruz, Michelle Grilley, Robert A. Schoenfeld, Craig S. Walker, Reshma P. Shetty, Robert M. Jones
-
Publication number: 20030065138Abstract: The invention relates to linear &ggr;-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: March 7, 2002Publication date: April 3, 2003Applicant: University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Craig S. Walker, Maren Watkins, Robert M. Jones
-
Publication number: 20030050435Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: ApplicationFiled: July 20, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Jacob Scott Nielsen, Robert M. Jones
-
Publication number: 20030050234Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Publication number: 20020198145Abstract: The present invention is directed to the new &mgr;O-conopeptides, their coding sequences and their propeptides and to the use of &mgr;O-conopeptides as a local anesthetic for treating pain. The &mgr;O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.Type: ApplicationFiled: July 20, 2001Publication date: December 26, 2002Applicant: COGNETIX, INC.Inventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, James E. Garrett, Richard T. Layer, John D. Wagstaff, Robert M. Jones
-
Publication number: 20020173449Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: December 28, 2000Publication date: November 21, 2002Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones